Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Rapoport

Showing results (151-160 of 179) with videos related to

Pageof 18
Sort By:
American Journal of Cancer Research|September 15, 2025
Outpatient axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma: ZUMA-24 primary analysisLori A Leslie, John H Baird, Ian W Flinn, et al.
British Journal of Haematology|September 9, 2021
The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphomaForat Lutfi, Noa G Holtzman, Ankit J Kansagra, et al.
Haematologica|October 16, 2025
CNS infiltration by zamtocabtagene autoleucel tandem CD20/CD19 CAR T cells leading to complete remission in a patient with primary CNS lymphomaNancy M Hardy, Jean A Yared, Tim Luetkens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cellsAaron P Rapoport, Edward A Stadtmauer, Nicole Aqui, et al.
Transplantation Proceedings|January 12, 2023
Outcomes of Busulfan, Fludarabine, and 400 cGy Total Body Irradiation Compared With Busulfan and Fludarabine Reduced-Intensity Conditioning Regimens for Allogeneic Stem Cell Transplantation in Adult Patients With Hematologic Diseases: A Single-Center ExperienceHanan Alkhaldi, Olga Goloubeva, Aaron P Rapoport, et al.
Blood|May 10, 2022
Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell-depleted lymphoma after CART therapyDjordje Atanackovic, Tim Luetkens, Destiny Omili, et al.
Haematologica|September 7, 2023
Immune-mediated facial nerve paralysis in a myeloma patient post B-cell maturation antigen-targeted chimeric antigen receptor T cellsYamini K Kathari, Haroon Ahmad, Michael E Kallen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2014
Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cellsAaron P Rapoport, Nicole A Aqui, Edward A Stadtmauer, et al.
Blood|October 30, 2010
Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myelomaAaron P Rapoport, Nicole A Aqui, Edward A Stadtmauer, et al.
Bone Marrow Transplantation|February 10, 2004
Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphomaG L Phillips, B R Meisenberg, D E Reece, et al.
Pageof 18

Showing results (151-160 of 179) with videos related to

Sort By:
Pageof 18
American Journal of Cancer Research|September 15, 2025
Outpatient axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma: ZUMA-24 primary analysisLori A Leslie, John H Baird, Ian W Flinn, et al.
British Journal of Haematology|September 9, 2021
The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphomaForat Lutfi, Noa G Holtzman, Ankit J Kansagra, et al.
Haematologica|October 16, 2025
CNS infiltration by zamtocabtagene autoleucel tandem CD20/CD19 CAR T cells leading to complete remission in a patient with primary CNS lymphomaNancy M Hardy, Jean A Yared, Tim Luetkens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cellsAaron P Rapoport, Edward A Stadtmauer, Nicole Aqui, et al.
Transplantation Proceedings|January 12, 2023
Outcomes of Busulfan, Fludarabine, and 400 cGy Total Body Irradiation Compared With Busulfan and Fludarabine Reduced-Intensity Conditioning Regimens for Allogeneic Stem Cell Transplantation in Adult Patients With Hematologic Diseases: A Single-Center ExperienceHanan Alkhaldi, Olga Goloubeva, Aaron P Rapoport, et al.
Blood|May 10, 2022
Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell-depleted lymphoma after CART therapyDjordje Atanackovic, Tim Luetkens, Destiny Omili, et al.
Haematologica|September 7, 2023
Immune-mediated facial nerve paralysis in a myeloma patient post B-cell maturation antigen-targeted chimeric antigen receptor T cellsYamini K Kathari, Haroon Ahmad, Michael E Kallen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2014
Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cellsAaron P Rapoport, Nicole A Aqui, Edward A Stadtmauer, et al.
Blood|October 30, 2010
Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myelomaAaron P Rapoport, Nicole A Aqui, Edward A Stadtmauer, et al.
Bone Marrow Transplantation|February 10, 2004
Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphomaG L Phillips, B R Meisenberg, D E Reece, et al.
Pageof 18